DK0895988T3 - Arylsulfonylaminohydroxamsyrederivater - Google Patents

Arylsulfonylaminohydroxamsyrederivater

Info

Publication number
DK0895988T3
DK0895988T3 DK98305959T DK98305959T DK0895988T3 DK 0895988 T3 DK0895988 T3 DK 0895988T3 DK 98305959 T DK98305959 T DK 98305959T DK 98305959 T DK98305959 T DK 98305959T DK 0895988 T3 DK0895988 T3 DK 0895988T3
Authority
DK
Denmark
Prior art keywords
aryl
hydroxamic acid
arylsulfonylamino hydroxamic
angiogenisis
occular
Prior art date
Application number
DK98305959T
Other languages
Danish (da)
English (en)
Inventor
Ralph Pelton Robinson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK0895988T3 publication Critical patent/DK0895988T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
DK98305959T 1997-08-08 1998-07-27 Arylsulfonylaminohydroxamsyrederivater DK0895988T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5520897P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
DK0895988T3 true DK0895988T3 (da) 2002-09-09

Family

ID=21996365

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98305959T DK0895988T3 (da) 1997-08-08 1998-07-27 Arylsulfonylaminohydroxamsyrederivater

Country Status (9)

Country Link
EP (1) EP0895988B1 (de)
JP (1) JPH11116549A (de)
AT (1) ATE217863T1 (de)
BR (1) BR9803128A (de)
CA (1) CA2244501C (de)
DE (1) DE69805473T2 (de)
DK (1) DK0895988T3 (de)
ES (1) ES2176913T3 (de)
PT (1) PT895988E (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8469601A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimiento para alquilar sulfonamidas impedidas estericamente
GT199900044A (es) * 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
WO2000058280A1 (en) * 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
DE60003863T2 (de) * 1999-03-31 2004-04-22 Pfizer Products Inc., Groton Dioxocyclopentylhydroxamsäure
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
RU2245876C2 (ru) 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
CA2401728A1 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
US6548667B2 (en) * 2000-04-07 2003-04-15 Samsung Electronics Co. Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
JP4294321B2 (ja) * 2001-03-14 2009-07-08 ノバルティス アクチエンゲゼルシャフト Mmp阻害剤としての使用のためのアザシクロアルキル置換酢酸誘導体
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
EP1452527B1 (de) 2001-11-13 2009-03-04 Shiseido Co., Ltd. Azabicycloverbindung, matrixmetallproteaseinhibitor und zubereitung für haut
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7504537B2 (en) 2001-12-27 2009-03-17 Dainippon Sumitomo Pharma Co., Ltd. Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
CA2549598A1 (en) * 2003-12-15 2005-06-30 Japan Tobacco Inc. N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
ZA200605248B (en) 2003-12-15 2007-10-31 Japan Tobacco Inc Cyclopropane compounds and pharmaceutical use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690703B2 (en) * 1994-06-22 1998-04-30 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0922030A1 (de) * 1996-08-23 1999-06-16 Pfizer Inc. Arylsulphonylamino-hydroxamsäure-derivate

Also Published As

Publication number Publication date
DE69805473D1 (de) 2002-06-27
ES2176913T3 (es) 2002-12-01
JPH11116549A (ja) 1999-04-27
CA2244501A1 (en) 1999-02-08
DE69805473T2 (de) 2003-01-16
CA2244501C (en) 2003-03-18
EP0895988A1 (de) 1999-02-10
BR9803128A (pt) 2000-05-02
PT895988E (pt) 2002-09-30
ATE217863T1 (de) 2002-06-15
EP0895988B1 (de) 2002-05-22

Similar Documents

Publication Publication Date Title
DE69805473D1 (de) Arylsulfonylaminohydroxamsäurederivate
CA2214720A1 (en) Arylsulfonylamino hydroxamic acid derivatives
EP0818442A3 (de) Cyclische Sulphonderivate als Metalloproteinase-Inhibitoren und zur Hemmung der Produktion von Tumornekrosefaktor
CA2218503A1 (en) Arylsulfonyl hydroxamic acid derivatives
ATE223215T1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
NZ330922A (en) Hydroxamic acid derivatives substituted by a series of 2-pyrrolidinones, hydantoins, and pyrazolidinones for use with the treatment of diseases related to connective tissue degradation
NO920702L (no) Hydroksaminsyrebaserte kollagenaseinhibitorer
GB2290543B (en) Hydroxamic acid derivatives as metalloproteinase inhibitors
YU37499A (sh) Derivati arilsulfonil hidroksamske kiseline
GB9902452D0 (en) Chemical compounds
CA2279276A1 (en) Arylsulfonylamino hydroxamic acid derivatives
PT900211E (pt) Tiadiazolil(tio)ureias uteis como inibidores de metaloproteases com matriz
CA2340138A1 (en) 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
BR9911010A (pt) Inibidores de sucinamida de enzima de conversão da interleucina-1beta
ATE402257T1 (de) Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
WO2000015208A3 (en) New use of immunosupressants for mmp-mediated diseases
DK0826681T3 (da) Epoxyravsyrederivater
CA2253796A1 (en) Inhibition of matrix metalloproteases by acetylene containing compounds
TNSN04055A1 (fr) Formes cristallines anhydres de gabapentine
TNSN05067A1 (en) Acetyl 2-hydroxy- 1,3 diaminoalkanes
UA35749A (uk) Спосіб лікування карієсу
IT1303766B1 (it) Alesatore-rettificatore di cavita' chirurgiche ossee destinate adaccogliere impianti.
ID21321A (id) Senyawa-senyawa betha-laktam untuk pengobatan penyakit infeksi disebabkan mikroorganisme penghasil betha-laktamase
BG107711A (bg) Нови м-амино-фенилимино-имидазолидин-производни за лечение на инконтиненция на урина